Drug Profile
YOB 1604
Alternative Names: YOB1604Latest Information Update: 22 Jan 2016
Price :
$50
*
At a glance
- Originator Yungjin Pharm Co
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 22 Jan 2016 Discontinued - Phase-I for Benign prostatic hyperplasia in South Korea (PO) prior to January 2016 (Yungjin Pharm's pipeline, January 2016)
- 15 Jul 2014 Phase-I clinical trials in Benign prostatic hyperplasia in South Korea (PO) prior to July 2014 (Yungjin Pharm's pipeline, July 2014)